The Johns Hopkins spinout has raised cash from OUP as it looks to move its first candidate, targeting skin itch complications, into the clinic.
Escient Pharmaceuticals, a US-based drug developer spun out of Johns Hopkins University, closed a $77.5m series B round on Monday backed by spinout-focused investment firm Osage University Partners (OUP).
Sanofi Ventures, the corporate venturing arm of pharmaceutical firm Sanofi, and Cowen Healthcare Investments (CHI) co-led the round, with further participation from Redmile Group and Perceptive Advisors.
All existing shareholders – which include Column Group and 5AM Ventures – returned for the round. Altitude Life Science Ventures’ Fund II…
